What is hot in idiopathic pulmonary fibrosis?

E-poster session
Chairs: M. Kreuter (Heidelberg, Germany), C. Valenzuela (Madrid, Spain)

Effects of nintedanib in patients with IPF: subgroup analysis by Charlson Comorbidity Index (CCI) E. Bendstrup (Aarhus, Denmark), F. Bonella (Essen, Germany), E. Bargagli (Siena, Italy), F. Caro (Buenos Aires, Argentina), M. Glassberg (Miami, FL, United States of America), B. Schinzel (Ingelheim am Rhein, Germany), M. Quaresma (Ingelheim am Rhein, Germany), L. Orsatti (Ingelheim am Rhein, Germany), I. Glaspole (Melbourne, Victoria, Australia)
Hiatus hernia and interstitial lung abnormalities P. George (London, United Kingdom), T. Hida (Boston, United States of America), R. Putman (Boston, United States of America), S. Desai (London, United Kingdom), A. Devaraj (London, United Kingdom), S. Kumar (London, United Kingdom), J. Mackintosh (Queensland, Australia), V. Gudnason (Reykjavik, Iceland), H. Hatabu (Boston, United States of America), G. Gudmundsson (Reykjavik, Iceland), G. Hunninghake (Boston, United States of America)
The effect of metformin on clinically relevant outcomes in 3,144 IPF patients from the EMPIRE registry D. Jovanovic (Beograd, Republic of Serbia), M. Šterclová (Prague, Czech Republic), N. Mogulkoc (Izmir, Turkey), K. Lewandowsk (Warsaw, Poland), V. Müller (Budapest, Hungary), M. Hájková (Bratislava, Slovakia), M. Kramer (Petah Tikva, Israel), J. Tekavec-Trkanjec (Zagreb, Croatia), M. Studnicka (Salzburg, Austria), N. Stoeva (Sofia, Bulgaria), B. Jovovska Kaeva (Skopje), S. Littnerová (Brno, Czech Republic), M. Roksandic Milenkovic (Beograd, Republic of Serbia), M. Vasakova (Prague, Czech Republic)
Clinical value of cluster analysis of unclassifiable idiopathic interstitial pneumonias phenotypes Y. Nakamura (Hamamatsu, Japan), T. Iwasawa (Yokohama, Japan), S. Matsushita (Kawasaki, Japan), Y. Terasaki (Tokyo, Japan), S. Kunugi (Tokyo, Japan), H. Kitamura (Yokohama, Japan), K. Mori (Hamamatsu, Japan), H. Yasui (Hamamatsu, Japan), T. Fujisawa (Hamamatsu, Japan), T. Suda (Hamamatsu, Japan)
Early decrease in erector spinae muscle area and future risk of mortality in idiopathic pulmonary fibrosis A. Nakano (Nagoya, Japan), H. Ohkubo (Nagoya, Japan), H. Taniguchi (Seto, Japan), Y. Kondoh (Seto, Japan), T. Matsuda (Seto, Japan), M. Yagi (Nagoya, Japan), T. Furukawa (Nagoya, Japan), Y. Kanemitsu (Nagoya, Japan), A. Niimi (Nagoya, Japan)
Primary results from the STARLINER study of disease behaviour in suspected ILD M. Wijsenbeek (Rotterdam, Netherlands), E. Bendstrup (Aarhus, Denmark), C. Valenzuela (Madrid, Spain), M. Henry (Cork, Ireland), C. Moor (Rotterdam, Netherlands), S. Jouneau (F-35000 Rennes, France), A. Fois (Sassari, Italy), O. Moran (Ontario, Canada), S. Anees (Windsor, Ontario, Canada), M. Mirt (Basel, Switzerland), M. Bengus (Basel, Switzerland), F. Gilberg (Basel, Switzerland), K. Kirchgaessler (Basel, Switzerland), C. Vancheri (Catania, Italy)
Reliability of home spirometry in idiopathic pulmonary fibrosis C. Moor (Rotterdam, Netherlands), R. Mostard (Heerlen, Netherlands), J. Grutters (Nieuwegein, Netherlands), P. Bresser (Amsterdam, Netherlands), J. Aerts (Rotterdam, Netherlands), N. Chavannes (Leiden, Netherlands), M. Wijsenbeek (Rotterdam, Netherlands)
Mapping IPF helps identify geographic regions at higher risk for disease development J. Shull (Barcelona, Spain), O. Jorba (Barcelona, Spain), C. Lara (Barcelona, Spain), M. Olid (Barcelona, Spain), M. Pay (Barcelona, Spain), G. Bermudo (Barcelona, Spain), G. Suarez Curatin (Barcelona, Spain), V. Vicens (Barcelona, Spain), L. Planas (Barcelona, Spain), J. Bordas (Barcelona, Spain), P. Rivera Ortega (Manchester, United Kingdom), M. Molina Molina (Barcelona, Spain), C. Group (Barcelona, Spain)
Low income and progression free survival in idiopathic pulmonary fibrosis: an association to  uncover L. Sese (Bobigny, France), J. Caliez (Bobigny, France), I. Annesi-Maesano (Paris, France), V. Cottin (Lyon, France), G. Pesce (Paris, France), M. Didier (Bobigny, France), Z. Carton (Bobigny, France), D. Israel-Biet (Paris, France), B. Crestani (Paris, France), S. Guillot Dudoret (Rennes, France), J. Cadranel (Paris, France), B. Wallaert (Lille, France), A. Tazi (Paris, France), B. Maître (Créteil, France), G. Prévot (Toulouse, France), S. Marchand-Adam (Tours, France), S. Hirschi (Strasbourg, France), S. Dury (Reims, France), V. Giraud (Boulogne, France), A. Gondouin (Besançon, France), P. Bonniaud (Dijon, France), J. Traclet (Lyon, France), K. Juvin (Paris, France), R. Borie (Paris, France), J. Bernaudin (Bobigny, France), D. Valeyre (Bobigny, France), C. Cavalin (Paris, France), H. Nunes (Bobigny, France)
Eligibility for anti-fibrotic therapy of patients in British Thoracic Society (BTS) UK IPF Registry varies according to the reference values used to calculate FVC P. Molyneaux (London, United Kingdom), M. Loughenbury (London, United Kingdom), S. Welham (London, United Kingdom), J. Hutchinson (Notingham, United Kingdom), H. Adamali (Bristol, United Kingdom), A. Fahim (Wolverhampton, United Kingdom), S. Agnew (Liverpool, United Kingdom), W. Funston (Gateshead, United Kingdom), S. Haney (Ashington, United Kingdom), L. Ho (Oxford, United Kingdom), J. Richardson (London, United Kingdom), H. Almond (Bury St Edmunds, United Kingdom), S. Jones (Bury St Edmunds, United Kingdom), L. Nicol (Edinburgh, United Kingdom), K. Spinks (Lymington, United Kingdom), A. Wilson (Norwich, United Kingdom), L. Spencer (Liverpool, United Kingdom)
Quantitative CT for the assessment of disease severity in interstitial lung disease D. Parr (Coventry (West Midlands), United Kingdom), E. Helm (Coventry (West Midlands), United Kingdom), J. Shakespeare (Coventry (West Midlands), United Kingdom), R. Hughes (Coventry (West Midlands), United Kingdom), A. Bhalerao (Warwick, United Kingdom)
The value of the surprise question to predict mortality in idiopathic pulmonary fibrosis N. Tak (Rotterdam, Netherlands), C. Moor (Rotterdam, Netherlands), C. Owusuaa (Rotterdam, Netherlands), C. Van Der Rijt (Rotterdam, Netherlands), M. Wijsenbeek (Rotterdam, Netherlands)
PREVALENCE AND CHARACTERISTICS OF PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS ADMITTED FOR PNEUMONIA ACQUIRED IN THE COMMUNITY. I. DOMINGUEZ ZABALETA (Madrid, Spain), J. De Miguel Diez (Madrid, Spain), V. Parra Leon (Madrid, Spain), Z. Ji (Madrid, Spain), A. Lopez De Andres (Madrid, Spain), V. Hernandez Barrera (Madrid, Spain), A. Cerezo Lajas (Madrid, Spain), L. Puente Maestu (Madrid, Spain), R. Jimenez Garcia (Madrid, Spain)
Pirfenidone in unclassifiable ILD (uILD): subgroup analysis of patients with/without a surgical lung biopsy (SLB) V. Cottin (Lyon, France), T. Corte (Camperdown, New South Wales, Australia), M. Kreuter (Heidelberg, Germany), M. Molina-Molina (Barcelona, Spain), J. Axmann (Basel, Switzerland), F. Gilberg (Basel, Switzerland), K. Kirchgaessler (Basel, Switzerland), T. Maher (London, United Kingdom)
Dynamics of diagnoses and pharmacotherapy before and after diagnosing idiopathic pulmonary fibrosis J. Rømhild Davidsen (Odense C, Denmark), L. Lund (Odense C, Denmark), C. Laursen (Odense C, Denmark), J. Hallas (Odense C, Denmark), D. Henriksen (Odense C, Denmark)
IMPACT OF IPF PATIENT SUPPORT PROGRAM IN QUALITY OF LIFE M. Molina Molina (Hospitalet de Llobregat, Spain), A. Garcia (Barcelona, Spain), L. Cobo (Barcelona, Spain), C. Ruiz (Barcelona, Spain), K. Portillo (Badalona, Spain), A. Boldova-Loscertales (Zaragoza, Spain), A. Robles-Perez (Mataró, Spain), J. Arribas (Zaragoza, Spain), J. Figuerola (Zaragoza, Spain), R. Blavia (Sant Joan Despi, Spain), Y. Belmonte (Sant Joan Despi, Spain), A. Moreno (Sabadell, Spain), D. Castillo (Barcelona, Spain), A. Villar (Barcelona, Spain), D. Badenes (Barcelona, Spain), E. Balcells (Barcelona, Spain), D. De Zayas (Barcelona, Spain), G. Suarez-Cuartin (Hospitalet de Llobregat, Spain), L. Garcia (Reus, Spain), J. Sellares (Barcelona, Spain), Y. Garcia (Huesca, Spain), S. Barril (Lleida, Spain), J. Sans (Terrassa, Spain), M. Serra (Tortosa, Spain), D. Perich (Manresa, Spain), L. Esteban (Terrassa, Spain), J. Dorca (Hospitalet de Llobregat, Spain), M. Garcia (Barcelona, Spain), P. Cerdá-Cortés (Barcelona, Spain), J. Palma (Hospitalet de Llobregat, Spain)